Table 5 Correlation between serum p53Abs and clinicopathologic features
From: Prognostic role of serum p53 antibodies in lung cancer
| Ā | No. of cases | No. of p53Ab-positive |
|---|---|---|
Age (years) | Ā | Ā |
ā¤60 | 47 | 11 (23.4%) |
>60 | 154 | 30 (19.5%) |
Sex | Ā | Ā |
Male | 157 | 29 (18.5%) |
Female | 44 | 12 (27.3%) |
Histological type | Ā | Ā |
NSCLC | Ā | Ā |
Adenocarcinoma | 79 | 10 (12.7%) |
Squamous cell carcinoma | 70 | 18 (25.7%) |
Bronchioloalveolar carcinoma | 6 | 0 (0%) |
Large cell carcinoma | 5 | 1 (20.0%) |
Anaplastic carcinoma | 19 | 5 (26.3%) |
Mixed carcinoma | 9 | 2 (22.2%) |
SCLC | 13 | 5 (38.5%) |
NSCLC stage | Ā | Ā |
I | 68 | 7 (10.3%) |
II | 24 | 7 (29.2%) |
III | 40 | 9 (22.5%) |
IV | 45 | 9 (20.0%) |
Missing | 11 | 4 (36.4%) |
Total | 188 | 36 (19.1%) |
II-IV | 109 | 25 (22.9%) |
NSCLC grade | Ā | Ā |
G1 | 4 | 0 (0%) |
G2 | 57 | 4 (7.0%) |
G3 | 72 | 18 (25.0%) |
Missing | 55 | 14 (25.5%) |
Total | 188 | 36 (19.1%) |